REMEDIUMREMEDIUM1561-59362658-3534Joint-Stock Company Chicot89810.21518/1561-5936-2021-3-11-22Original ArticleOverview of the Russian market of herbal productsSafonovaNatalia V.-TrofimovaElena O.-Evalar JSCSt Petersburg State Chemical Pharmaceutical University151220213112218032022Copyright © 2021,2021Introduction. In the Russian pharmaceutical market, there is the following situation: herbal medicinal products (HMP) and dietary supplements based on plant raw materials (DS) have similar compositions, dosage forms and scope of application. They’re often considered analogues by consumers and specialists, which indicates the existence of common market for these products.Research aim is to investigate the state and development trends of the Russian HMP and DS market, assessing positions of foreign and domestic companies and general prospects for this market as well.Methodology. The study was conducted using IQVIA retail audit database, official sources of information on HMP and DS registration. In the market analysis the products were classified depending on the scope of application, composition and preparation methods, and dosage forms as well.Results. In 2020 pharmacy of HMP and DS sales amounted to 435.4 million units valued at 51.3 billion rubles in wholesale prices. Beginning with 2016, the average annual growth rate corresponded to 4.2%, in value terms. However, in volume terms, the sales were reduced in the average by 3.4% per year (due to cheap domestic medicines). The main part of the entire market comprises HMP (80% in units and 74% in value terms in 2020). The products, affecting respiratory system, genitourinary sphere, and digestion, provide more than three-quarters of all sales in value terms. More than half of the market is occupied by total extractive drugs. Solid dosage forms (tablets and capsules) account for half of the sales, plant raw materials and fees constitute more than one third. In 2020, Russian companies provided 28% of the sales of HMP and 67% of DS in value terms. In the context of the main segments, the market structure in 2016-2020 remained fairly stable.Conclusion. In the future, the market dynamics in value terms will be determined considering by household income and the epidemiological situation. In units, HMP sales will continue to decline through the unprofitable positions of the traditional domestic drug assortment. The increasing strictness of legislation requirements for the market of dietary supplements may contribute to investment in the development of HMP that are competitive to foreign products in terms of quality and consumer characteristics.Russian pharmaceutical marketherbal medicinal productsdietary supplementsроссийский фармацевтический рынокрастительные лекарственные препаратыбиологически активные добавки1.Shikov A.N., Pozharitskaya O.N., Makarov V.G., Wagner H., Verpoorte R., Heinrich M. Medicinal plants of the Russian Pharmacopoeia; their history and applications. J Ethnopharmacol. 2014;154(3):481–536. https://doi.org/10.1016/j.jep.2014.04.007.2.Herbal Medicine Market – Global Market Share, Trends, Analysis and Forecasts, 2020–2030. InsightSLICE, 2021. Available at: https://www.insightslice.com/herbal-medicine-market.3.Bilia A.R. Herbal medicinal products versus botanicalfood supplements in the European market: state of art and perspectives. Nat Prod Commun. 2015;10(1):125–131. Available at: https://journals.sagepub.com/doi/pdf/10.1177/1934578X1501000130.4.Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use.5.Directive 2004/24/EC of the European Parliament and of the Council of 31 March 2004 amending, as regards traditional herbal medicinal products, Directive 2001/83/EC on the Community code relating to medicinal products for human use.6.Council directive 2002/46/EC of 10 June 2002 on the approximation of the laws of the member states relating to food supplements.7.Правила регистрации и экспертизы лекарственных средств для медицинского применения (утверждены Решением Совета ЕЭК от 3 ноября 2016 г.). Режим доступа: https://docs.cntd.ru/document/456026097.8.Рекомендация Коллегии Евразийской экономической комиссии от 10 мая 2018 г. №6 «О Руководстве по качеству лекарственных растительных препаратов». Режим доступа: https://www.garant.ru/products/ipo/prime/doc/71842602/#1000.9.Государственная фармакопея Российской Федерации 14-го издания. ОФС.1.5.1.0001.15. Режим доступа: https://nevacert.ru/reestry/pharmacopoeia/ofs.1.5.1.0001.15.10.Фармвестник. Режим доступа: https://pharmvestnik.ru/content/news/Prodaji-samoi-populyarnoi-nastoiki-v-2020-godu-sostavilipochti-29-mln-upakovok.html.11.Филиппова И. Рынок растительных средств: проблемы, перспективы, приоритеты. Ремедиум. 2016;(7–8):15–16.12.Акамова А.В., Немятых О.Д., Наркевич И.А. Многовекторный маркетинговый анализ российского рынка фитопрепаратов. Разработка и регистрация лекарственных средств. 2017;(4): 276– 280. Режим доступа: https://www.pharmjournal.ru/jour/article/view/528/523.13.Афанасьева Т.Г., Дремова Н.Б., Киселева Т.Л. Динамика основных показателей отечественного рынка официнальных растительных препаратов в первом десятилетии ХХI века. Традиционная медицина. 2013;3(34):28–35. Режим доступа: https://www.tradmed.ru/index.php/tm/article/view/368/395.14.Бойко Н.Н., Бондарев А.В., Жилякова Е.Т., Писарев Д.И., Новиков О.О. Фитопрепараты, анализ фармацевтического рынка Российской Федерации. Научные результаты биомедицинских исследований. 2017;(4):30–38. Режим доступа: https://cyberleninka.ru/article/n/fitopreparaty-analiz-farmatsevticheskogo-rynka-rossiyskoy-federatsii.15.Алиева Н.А. Маркетинговые исследования поведения потребителей органических растительных лекарств. Central Asian Economic Review. 2021;(6):171–183. Режим доступа: https://caer.elpub.ru/jour/article/viewFile/108/109.16.Гаммель И.В., Суворова О.В., Запорожская Л.И. Анализ тенденций российского рынка биологически активных добавок к пище. Медицинский альманах. 2017;6(51):154–158. Режим доступа: https://cyberleninka.ru/article/n/analiz-tendentsiy-rossiyskogorynka-biologicheski-aktivnyh-dobavok-k-pische.17.Трофимова Е.О., Гетьман М.А. Классификация лекарственных средств с точки зрения особенностей потребительского поведения. Ремедиум. 2002;(5):22–28.18.Приложение 7 к техническому регламенту Таможенного союза «О безопасности пищевой продукции» (ТР ТС 021/2011). Режим доступа: https://docs.cntd.ru/document/902320560.19.Каухова И.Е., Минина С.A. Химия и технология фитопрепаратов. М.: ГЭOTAP-Meдиа; 2004. 560 с. Режим доступа: https://www.fptl.ru/biblioteka/lekarstva/fitopreparati.pdf.20.Самылина И.А., Северцев В.А. (ред.). Лекарственные растения государственной фармакопеи. Фармакогнозия. М.: АМНИ; 1999. 93 с.